Compare Mesoblast Limited (MESO) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Oxford Lane Capital Corp — how do they compare? Mesoblast Limited trades at $16.23 (market cap $2.17B), while Oxford Lane Capital Corp trades at $8.98 (market cap $866.15M). The key difference: Mesoblast Limited is far larger — about 2.5× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 27.06% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | OXLC | |
|---|---|---|
Market Cap | $2.17B | $866.15M |
Sector | Technology | Financials |
52-Week High | $20.96 | $19.90 |
52-Week Low | $12.88 | $8.15 |
Enterprise Value | $2.17B | — |
Dividend Yield | — | 27.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
OXLC trades at $8.87, up 1.14% today, but faces a bearish technical outlook with negative moving averages and oscillators. The stock shows mixed fundamentals with a low P/B of 0.83 but alarming profitability metrics including a -39.16% ROE and three consecutive quarterly EPS misses. Recent news highlights concerns over its 24% dividend yield sustainability and a sharp net asset value decline reported in May 2026.
The outlook is cautious due to deteriorating earnings, high dividend risks, and negative cash flow from operations. While the P/B ratio suggests potential undervaluation, significant headwinds from poor ROE, volatile revenue, and bearish analyst sentiment outweigh opportunities. Investors should prioritize risk management amid ongoing financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
